Precision KOL mapping and advocacy
Find the right partners and connect with them in the right way.
With the growing international trend towards micro-targeting and demonstrating real value in patient outcomes, it is essential that you precision-identify the right external healthcare professionals to work with.
The success of your interactions depends on creating mutually beneficial partnerships, based on well-matched interests and goals.
Have you found exactly the right people to:
- Collaborate in clinical trials
- Chair or participate in advisory boards
- Speak at congresses and conferences
- Participate in a rising stars programme
- Develop peer-to-peer publications programmes
- Host digital engagement strategies
- Curate patient advocacy and education activities?
Illuminatis offers specialist techniques for identifying different types of target KOL:
With over 25 years’ experience at global, regional and national levels, Illuminatis has developed sophisticated methodologies of data gathering and data processing algorithms to optimise all aspects of Key Opinion Leader (KOL) identification, management and engagement. Our methodologies are designed to be data protection compliant.
We have experience in a wide range of therapy areas and complex markets for pharmaceuticals, biotech, diagnostics and devices, nutrition or emerging sectors such as digital therapeutics.
Our projects are all delivered using highly experienced and qualified staff, whilst fully leveraging highly cost-effective and flexible pricing models.
Broad geographical reach:
Europe (including Eastern Europe), North and South America, Australasia, Asia (with particular experience in Japan and China) and the Middle East.
Extensive range of therapy areas:
Including particular expertise in oncology, cardiology, endocrinology, diabetes, obesity, dermatology, nephrology, vaccines, haematology, allergy and immunology, hepatology, women’s health, nephrology, respiratory medicine, neurology, ophthalmology, pathology, psychiatry, surgery, dental health, neonatal medicine and rare diseases.